Early acute toxicities associated with radiotherapy (RT) can compromise cancer treatment and, in the most extreme cases, lead to radiotherapy discontinuation. Predicting these toxicities is therefore a medical, social and economic challenge. Among the various factors involved in these toxicities, such as clinical and/or dosimetric factors, it is currently accepted that a large part of the risk of toxicity is due to individual radiosensitivity.
This makes radiosensitivity prediction tests a valuable decision-making tool, whether for the choice of fractionation, therapeutic modality (e.g. surgery) or type of radiation (protons vs. photons). In recent years, many teams have tried unsuccessfully to implement radiosensitivity predictive tests in clinical routine.
The RadioDtect© test from Neolys Diagnostics
Our laboratory has developed a new radiosensitivity prediction test called RadioDtect®. This binary test is based on the quantification of the pATM protein in lymphocytes.
It can be used to predict the risk of toxicity for a given patient. We carried out a study to demonstrate the performance and validate RadioDtect® in two different cohorts: a first cohort of 150 patients with several types of cancer; a second cohort of 36 patients with head and neck cancers.
The results obtained show promising performance for this test (AUC of 77%). This study provides the basis for an easy-to-perform test for clinical use.
Stay informed with our free relationship program for outreach professionals.
Distribution, R&D, clinical tests…